AxoGen Inc 2025年季度报告

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549FORM10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 OR Axogen,Inc. (Exact Name of Registrant as Specified in Its Charter) Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to Table of Contents Part I - Financial Information Condensed Consolidated Balance Sheets as ofMarch 31, 2025and December 31, 2024(Unaudited)3Condensed Consolidated Statements of Operations for the threemonthsendedMarch 31, 2025and 2024(Unaudited)4Condensed Consolidated Statements of Cash Flows for thethreemonths endedMarch 31, 2025and 2024(Unaudited)5Condensed Consolidated Statements of Changes in Shareholders’ Equity for the three months ended March 31,2025 and 2024 (Unaudited)6Notes to Unaudited Condensed Consolidated Financial Statements7 Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations Item 3.Quantitative and Qualitative Disclosures About Market Risk Part II - Other Information Item 2.Unregistered Sales of Equity Securities and Use of Proceeds Item 5.Other Information25 Item 6.Exhibits26 Signatures27 Forward-Looking Statements From time to time, in reports filed with the United States (“U.S.”) Securities and Exchange Commission (the “SEC”) (includingthis Quarterly Report on Form 10-Q), in press releases, and in other communications to shareholders or the investment community,Axogen, Inc. (including Axogen, Inc.’s wholly owned subsidiaries, Axogen Corporation, Axogen Processing Corporation, AxogenGermany GmbH and Axogen Europe GmbH, the “Company,” “Axogen,” “we,” “our,” or “us”) may provide forward-lookingstatements, as defined in the Private Securities Litigation Reform Act of 1995, concerning possible or anticipated future results ofoperations or business developments. These statements are based on management’s current expectations or predictions of future The forward-looking statements in this Form 10-Q include, but are not limited to, the following: •Our belief that we will continue to drive growth in the nerve protection category; and Our belief that our existing cash and cash equivalents and investments, as well as cash provided by sales of our products willallow us to fund our operations through at least the next twelve months. The forward-looking statements are and will be subject to risks and uncertainties, which may cause actual results to differmaterially from those expressed or implied in such forward-looking statements. Forward-looking statements contained in thisQuarterly Report on Form 10-Q should be evaluated together with the many risks and uncertainties that affect the Company’s businessand its market, particularly those discussed in the risk factors and cautionary statements set forth in the Company’s filings with theSEC, including as described in “Risk Factors” included in Item 1A and “Risk Factor Summary” included in the Company's Annual Axogen,Inc.Condensed Consolidated Balance Sheets Axogen,Inc.Condensed Consolidated Statements of Operations Axogen,Inc.Notes to Condensed Consolidated Financial Statements 1.Nature of Business Axogen, Inc. (together with its wholly-owned subsidiaries, the “Company”) was incorporated in Minnesota. The Company’sbusiness is focused on the science, development and commercialization of the technologies used for peripheral nerve regeneration and repair. The Company’s products include AvanceNerve Graft, Axoguard Nerve Connector,Axoguard Nerve Protector,AxoguardHA+ Nerve Protector™, Axoguard Nerve Capand Avive+ Soft Tissue Matrix™.The Company is headquartered in Florida. The Company has processing, warehousing and distribution facilities in Ohio and Texas.The Company manages its operations as a single operating segment. Substantially all of the Company’s assets are maintained inthe United States (“U.S.”). The Company derives substantially all of its revenues from sales to customers in the U.S. 2.Summary of Significant Accounting Policies Please see Note 2 to the Company’s consolidated financial statements included in the Company’s Annual Report on Form 10-Kfor the year ended December31, 2024, filed with the Securities and Exchange Commission on February 26, 2025, for a description ofall significant accounting policies. Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company as of March31,2025 and December31, 2024 and for the three months ended March31, 2025 and 2024. The Company’s condensed consolidatedfinancial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X andtherefore do not include all information and footnotes necessary for a fair presentation